63 completed, 15 unknown, 7 terminated, 5 recruiting. 46 Not applicable, 16 Phase 1, 12 Phase 2, 9 Phase 3, 7 Phase 4.
Follow Glucagon-Like Peptide 1: new trials by email Literature Review of Glucagon-Like Peptide 1 trials Research Report on Glucagon-Like Peptide 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry GLP-1 / GIP receptor agonist - Heart Failure With Preserved Ejection Fraction, Obesity | Not yet recruiting | Miedziowe Centrum Zdrowia SA | 150 | 2027-01-01 | 2026-08-26 | |
| The Effects of LEUVATE on Glycemia, Insulinemia, Aminoacidemia, and Protein Synthesis in GLP-1 RA-treated Adults GLP-1 - The Whole-body Protein Synthesis Response to Protein With Amino Acid or Amino Acids | Not applicable | Not yet recruiting | Nutraceutical Innovations LLC | 8 | 2026-06-01 | 2026-05-20 |
| Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion GIP, GLP-1, Saline (0.9% Sodium Chloride) - Type 2 Diabetes, Healhty | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 36 | 2026-03-12 | 2026-10-27 |
| Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes Incretin-based therapies (GLP-1 and GLP-1/GIP) - Obesity | Enrolling by invitation | Indiana University | 125000 | 2026-01-01 | 2026-06-10 | |
| People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists GLP-1, Ocrelizumab (US) - Multiple Sclerosis | Recruiting | Northwestern University | 100 | 2025-11-15 | 2026-03-17 | |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes lixisenatide + glargine, Intensive insulin therapy - Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia | Phase 4 | Enrolling by invitation | Medical University of Warsaw | 100 | 2025-07-10 | 2025-09-19 |
| Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity GLP-1, CBTe Group Therapy - Binge Eating Disorder Associated With Obesity, Binge Eating Disorder | Recruiting | Haukeland University Hospital | 80 | 2025-07-01 | 2025-09-15 | |
| Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures GLP-1, Placebo - Longevity, Quality of Life | Early Phase 1 | Enrolling by invitation | AgelessRx | 150 | 2024-11-01 | 2025-07-30 |
| Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention Metformin, GLP-1A, MED - Prediabetes / Type 2 Diabetes | Phase 4 | Not yet recruiting | Stanford University | 200 | 2024-11-01 | 2024-11-12 |
| Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Omarigliptin, Sulphonylureas, Metformin - Type2diabetes | Phase 4 | Unknown | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 938 | 2024-09-01 | 2024-07-16 |
| GLP-1 Medicines and Mental Health Changes GLP-1 - Obesity, Depression | Not applicable | Completed | University of California, San Diego | 90 | 2024-05-01 | 2026-01-27 |
| Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1) - Diabetes Mellitus, Type 2 | Completed | Novo Nordisk A/S | 156 | 2024-04-30 | 2025-03-21 | |
| A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System Dasiglucagon, GlucaGen - Diabetes Mellitus, Type 1 | Phase 2 | Withdrawn | Inreda Diabetic B.V. | 2023-12-29 | 2024-01-03 | |
| High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program phone calls and encouraging patients' lifestyle change and medication adherence, Statin - Cardiovascular Diseases, Diabetes Mellitus, Type 2 | Not applicable | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 16000 | 2023-01-15 | 2023-12-15 |
| The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function GIP(1-42), GLP-1, GLP-2 - Incretin Effect | Not applicable | Completed | University of Copenhagen | 50 | 2023-01-04 | 2026-04-29 |
| Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes GlucaGen - Type 1 Diabetes, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 10 | 2022-09-21 | 2025-08-29 |
| Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes GlucaGen, Saline - Type 1 Diabetes, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 22 | 2021-11-23 | 2023-12-05 |
| Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes Glucagon, Closed-loop System - Type 1 Diabetes | Phase 4 | Completed | Steno Diabetes Center Copenhagen | 11 | 2021-05-20 | 2022-08-18 |
| Glucagon-like Peptide-1 in Type 1 Diabetes Glucagon-like peptide-1, Placebos - Type1 Diabetes Mellitus | Early Phase 1 | Withdrawn | University of Maryland, Baltimore | 2020-06-24 | 2025-11-10 | |
| L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells. - Severe Obesity, Type 2 Diabetes Mellitus in Obese | Not applicable | Unknown | University of Sao Paulo General Hospital | 20 | 2020-02-05 | 2022-07-11 |
Showing 20 of 102. Sign in to see all of them.
Diabetes Mellitus, Type 2 (27) · Diabetes Mellitus, Type 1 (17) · Hypoglycemia (17) · Obesity (15) · Diabetes Mellitus (14) · Insulin Resistance (10) · Myocardial Infarction (4) · Heart Failure (3) · Hyperglycemia (3) · Cardiovascular Diseases (2) · Coronary Disease (2) · Cystic Fibrosis (2) · Glucose Metabolism Disorders (2) · Inflammation (2) · Irritable Bowel Syndrome (2)
University Hospital, Gentofte, Copenhagen (6) · Hvidovre University Hospital (5) · Copenhagen University Hospital, Rigshospitalet (4) · Steno Diabetes Center Copenhagen (4) · University of Aarhus (4) · University of Copenhagen (4) · Johns Hopkins University (3) · Legacy Health System (3) · Zealand Pharma (3) · Eli Lilly and Company (2) · Indiana University (2) · Mayo Clinic (2) · Mikkel Christensen (2) · Novo Nordisk A/S (2) · Papworth Hospital NHS Foundation Trust (2)
Denmark (32) · United States (30) · Germany (9) · United Kingdom (6) · China (5) · Austria (3) · Canada (3) · Sweden (3) · Norway (2) · Poland (2) · Australia (1) · Bangladesh (1) · Belgium (1) · Brazil (1) · Finland (1)
Dariush Elahi, PhD (3) · Christina Sylvest, MSc Pharm (2) · Sissel B Lundemose, MD (2) · W Kenneth Ward, MD (2) · Adrian Vella, MD (1) · Ajenthen Ranjan, MD (1) · Ali Asmar, MD, PhD (1) · Ania Jastreboff, Phd,MD (1) · Astrid Plamboeck, M.D. (1) · Ayman M Arafat, Dr.med. (1) · Birgitte Brock, MD (1) · Birgitte Brock, asso.prof. (1) · Carel W le Roux, PhD MB FRCP (1)
PMID 24400077, PMID 38444629, PMID 18292985, PMID 18298441, PMID 19037628, PMID 19094067, PMID 20805279, PMID 22517769, PMID 23599045, PMID 23966238, PMID 24516103, PMID 24735885, PMID 24891019, PMID 25053587, PMID 25158865, PMID 25675385, PMID 26043228, PMID 26341131, PMID 26445112, PMID 26542491, PMID 26567860, PMID 26573925, PMID 26908914, PMID 27143183, PMID 28096259, PMID 29099978, PMID 29177486, PMID 29273578, PMID 30598343, PMID 31203378, PMID 31277053, PMID 32514794, PMID 32518064, PMID 33103603, PMID 34016263, PMID 34097062, PMID 35111398, PMID 35239971, PMID 35363252, PMID 35729365, PMID 35796669, PMID 35994729, PMID 36260533, PMID 36734354, PMID 36933790, PMID 38427076, PMID 8550855, PMID 9525985
2005 (1), 2008 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), 2025 (1), R01DK061644 (1), R01DK102359 (1), R21HL092799 (1), U24DK100469 (1), UL1RR024150 (1)